Benchmark Maintains Buy on Agilon Health, Raises Price Target to $140
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Benchmark analyst Bill Sutherland maintains Agilon Health (NYSE:AGL) with a Buy and raises the price target from $95 to $140.
Benchmark analyst Bill Sutherland maintains Agilon Health (NYSE:AGL) with a Buy and raises the price target from $95 to $140.